Alteon starts Ph IIb trial of ALT-711 in ISH

10 July 2001

Alteon has started a Phase IIb trial, called SAPPHIRE, which willevaluate the firm's Advanced Glycosylation Endpoint Crosslink Breaker compound, ALT-711, in patients with isolated systolic hypertension. The orally-active compound has already been shown in a Phase IIa trial to lower systolic blood pressure and pulse pressure in aging and diabetic patients (Marketletters passim).

SAPPHIRE will enrol 450 patients who will receive ALT-711 once-daily for six months, on top of existing medications. The drug is thought to work by breaking the pathological bonds that cause tissues, organs and blood vessels to stiffen and lose function over time.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.